The Private Equity fund of Gilde Healthcare acquires German medtech company Acti-Med - Gilde Healthcare

The Private Equity fund of Gilde Healthcare acquires German medtech company Acti-Med

April 27, 2021

Investment to support the global expansion of leading manufacturer of precision medical components and devices

Utrecht (the Netherlands) and Freienstau – The Private Equity fund of Gilde Healthcare, a specialist healthcare investor, has acquired Acti-Med, a leading international developer and contract manufacturer of high-quality medical components and devices for the medical and pharmaceutical industries.

Founded in 1997, Germany-based Acti-Med focuses on tailor-made, highly regulated, cannulas and cannula systems for pharmaceutical and medical applications, jointly developed with international Original Equipment Manufacturers (OEMs). Headquartered in Freiensteinau (Germany) and with operations in Kozerkí (Poland), Acti-Med has attracted clients from all around the world by combining the highest development and engineering capabilities, offering superior quality and operational flexibility. Recent expansions into promising adjacent end markets, supported by innovative best-in-class products highlight the company’s ambitions for growth.

Gilde Healthcare will collaborate with Acti-Med to further strengthen and expand its product portfolio in both the Ready for Market and Ready for Clean room segments, as well as further expand its manufacturing and design capacity to serve its increasing demands from its Pharma and Medical Device customers.

Andreas Schwalb, Founder and CEO of Acti-Med added:

“Acti-Med has had a truly exciting journey over the last 24 years and I am proud to look back on how we have grown our company from scratch into a global leader in our field. I would like to thank everyone at Acti-Med for their invaluable contributions. Now is the right time in our development to bring significant new investment and competencies to support our growth. We are pleased to have attracted Gilde Healthcare, who bring deep sector knowledge and a constructive, collaborative mindset. I look forward to working with Gilde Healthcare for Acti-Med’s successful future.”

Rafael Natanek, Partner at Gilde Healthcare, added:

“We are pleased to complete this acquisition of Acti-Med, a highly regarded contract manufacturer of tailor-made cannula and cannula systems with promising growth opportunities. The company has, through its design-skills, high-quality manufacturing, and flexibility to achieve rapid growth. We are excited to be investing in the company’s continued growth and look forward supporting the management as we consider additional options, such as strategic acquisitions.”

The shareholders of Acti-Med have been advised by DZ BANK Corporate Finance as exclusive M&A advisor.

 

Media contacts:
LifeSci Advisors
Frank Schwarz – fschwarz@lifesciadvisors.com / +49 17 26 15 31 60

Gilde Healthcare
Rafael Natanek – natanek@gildehealthcare.com / +31 61 18 44 63 0

About Acti-Med

Acti-Med is one of the leading manufacturers in the field of medical technology. Headquartered in Freiensteinau, Germany Acti-Med’s competence lies in the development and production of cannulas and cannula systems. Acti-Med develops, produces and sells high-quality medical components and devices for medical and pharmaceutical industries. Our customers are located throughout a wide range of industries, including oncology, pain therapy, the pharmaceutical industry and veterinary medicine. www.acti-med.de.

About Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion across two fund strategies: Private Equity and Venture & Growth. Gilde Healthcare Private Equity participates in profitable European lower mid-market healthcare companies with a prime focus on the Benelux and DACH region. The Private Equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. Gilde Healthcare Venture & Growth invests in medtech, healthtech and therapeutics in Europe and North America.
For more information, visit the company’s website at www.gildehealthcare.com

Gilde Healthcare company Noema Pharma Announces First Patients Dosed in Phase 2b Study for Tourette Syndrome

Phase 2b study will evaluate the safety and efficacy of gemlapodect (NOE-105) in patients with Tourette syndrome Noema Pharma AG, a clinical-stage neuroscience-based company, today announced the first patients have been dosed in a global...
October 30, 2024

Gilde Healthcare invests in SynOx Therapeutics and company doses first patients in Phase 3 trial

Gilde Healthcare Leads Series B Extension, Joining Premier Syndicate of Leading Life Science Investors Funding Supports Registrational Phase 3 TANGENT Trial of Emactuzumab, a Best-in-Class CSF-1 Receptor Targeted Antibody, for the Treatment of Tenosynovial Giant...
October 30, 2024

Gilde Healthcare company Lumicks secures €20 Million from European investment bank to accelerate drug discovery

Amsterdam-based LUMICKS signs €20 million venture debt with EIB to accelerate the development and launch of its new product, designed to advance immunotherapy development for cancer research. LUMICKS’ next generation high-throughput cell avidity platform aims...
October 10, 2024